NCT02248077View on ClinicalTrials.gov

A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2016

Conditions
Impaired Wound Healing
Interventions
DEVICE

AutoloGel

OTHER

Usual and Customary Care (UCC)

Sponsors

Lead Sponsor

Cytomedix
All Listed Sponsors
lead

Cytomedix

INDUSTRY

NCT02248077 - A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers | Biotech Hunter | Biotech Hunter